20S proteasome and its inhibitors: crystallographic knowledge for drug development.
about
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropicaProteasome inhibition by fellutamide B induces nerve growth factor synthesisComputational Approaches for the Discovery of Human Proteasome Inhibitors: An OverviewLessons from the past and charting the future of marine natural products drug discovery and chemical biologyTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesStructural Analysis of Spiro β-Lactone Proteasome InhibitorsInhibitors selective for mycobacterial versus human proteasomesStructural Insights on the Mycobacterium tuberculosis Proteasomal ATPase MpaStructural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasomeFellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasomeCharacterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunitElucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibitionSynthesis and biological activity of optimized belactosin C congenersHydroxyureas as noncovalent proteasome inhibitorsEnzyme Inhibition by Hydroamination: Design and Mechanism of a Hybrid Carmaphycin-Syringolin Enone Proteasome InhibitorDifferential global structural changes in the core particle of yeast and mouse proteasome induced by ligand bindingA Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome InhibitorsHexameric assembly of the proteasomal ATPases is templated through their C terminiTrial Watch: Proteasomal inhibitors for anticancer therapyRecent Advances in Nucleophilic Addition Reactions of Organoboronic Acids and Their Derivatives to Unsaturated CN FunctionalitiesRecognition and processing of ubiquitin-protein conjugates by the proteasomeUnderstanding the mechanism of proteasome 20S core particle gating.Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamidesComparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome.Osmotic stress inhibits proteasome by p38 MAPK-dependent phosphorylation.Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells.Advances in and applications of proteasome inhibitorsOxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.Recent advances in proteasome inhibitor discovery.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.Regulated protein turnover: snapshots of the proteasome in action.Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA).
P2860
Q24646019-E4607600-92C3-415F-B258-4CDF1315BBA3Q24654152-C4BBE558-80C9-4506-A4B7-7F8ECF0E15ACQ26738752-A5BD9882-B370-46E3-BCE8-35F9E920111EQ26863108-7E08B868-844B-4B5C-8148-1AD8F31D4998Q27026951-1D837F15-B61C-4567-90FB-43A6EDCC6033Q27652533-D0391528-B3F9-4248-9912-C1B522B943EAQ27657451-B64E2539-391B-482D-9B10-E3AB805D6EAFQ27657813-3423F313-3AE7-46B4-A295-64BDBBEAEB7BQ27661499-4B098080-CF48-4994-86BA-A0CD6F3AE0C2Q27662412-78EF6C28-1673-4175-8E51-EEE8D4205B04Q27663486-5790F620-757A-4ED7-9428-98922536FFC3Q27666372-CEC4FDFA-3142-48A9-860D-B8FE273FC72EQ27674459-E5B91429-3A22-4EB5-BC98-94008E2C1F86Q27675743-0D4DD042-9229-49A5-82BF-BA75FC3D8301Q27684346-FFD75C96-2E76-436F-B1AB-B3F97BD3FB01Q27684495-EF632FA4-6ECB-41D6-974F-8A5167CCA991Q27700842-19541E5D-3F9F-4905-8072-3C9AC67897D2Q27931123-061F2BF4-A092-400E-A91B-D2976C51AE07Q28082910-72828FC8-48F1-44A2-AE5A-FD2E48A75BC0Q29400231-00E3A044-3B77-4A12-AB75-AA0B67AD1871Q29547616-15A0EE63-0405-4395-919F-90F0B2AD8E35Q30794898-A535D867-AE30-4A63-A31A-5E8F480001F5Q33766685-76A9EE1B-C7DB-48FD-8D11-9DCFD29AA1FFQ33836952-18707617-5769-492A-AF70-23C3F940C5C1Q33884616-7954FA76-0EBD-4EC3-AC0D-2145003A7285Q34079904-2F30DB71-3C87-4EA4-AC65-D5DFC6DCAF07Q34142223-F9A518A8-3E5A-47E6-9949-F7E655CB70BEQ34195083-00178241-1C76-4FF4-B86C-6E0C22D00D60Q34282526-6A285593-DCC7-4C11-9747-DDE973712910Q34438701-EDD59FA1-9076-4FAF-8A62-61535FBAAA34Q34520431-3498A14D-3DF1-4B3F-A824-811DB3A031DFQ34594744-C5BEAB04-B83E-45ED-8FA8-5BB161DAD7E1Q34644848-1C19DAEF-1A35-4A24-9862-B0B7B0244C3FQ34645067-F189F616-B18B-4205-9230-46774F8FA43AQ34788381-757A7A0B-8B8E-43FD-A032-AA62B147B051Q35107386-2CCB85B9-D29F-485F-A76D-751ED85BFC15Q35150882-C52B2629-30B1-402C-B575-F74683A8644FQ35257872-DE9A6530-4377-40D1-9360-D0F5F21ED287Q35269634-E962B128-107F-4EE0-9774-5500CA570682Q35756052-B612E152-2979-4137-94D9-E361E099B4C9
P2860
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@ast
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@en
type
label
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@ast
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@en
prefLabel
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@ast
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@en
P356
P1433
P1476
20S proteasome and its inhibitors: crystallographic knowledge for drug development.
@en
P2093
Ljudmila Borissenko
Michael Groll
P304
P356
10.1021/CR0502504
P577
2007-02-23T00:00:00Z